AstraZeneca announces positive results from MATTERHORN phase III trial of Imfinzi in combo with standard─of─care FLOT in ...
Positive high-level results from the MATTERHORN phase III trial showed perioperative treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy …